Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31407Editorial articleПередовая статьяReview ArticleDengue fever in Russian tourists who have come from ThailandЛихорадка Денге у российских туристов, прибывших из ТаиландаShestakovaI VШестаковаИ Вshes.irin@mtu-net.ruIushchukN DЮщукН Дshes.irin@mtu-net.ruAkinfievI BАкинфиевИ БPopovaT IПоповаТ ИSergeevaT VСергееваТ ВVdovinaE TВдовинаЕ ТМГМСУ им. А.И. ЕвдокимоваИнфекционная клиническая больница №2, Москва151120138511VOL 85, NO11 (2013)ТОМ 85, №11 (2013)11512410042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31407

The review analyzes the major epidemiological and clinical aspects of Dengue fever, by providing the clinical examples of using its imported cases. It gives algorithms for examining patients who have come from tropical countries with the fever of unknown origin. Based on the extensive data available in the literature and international guidelines, the authors present treatment algorithms for out- and inpatients with Dengue fever. Promising studies of vaccination against Dengue fever are analyzed.

Аннотация. В обзоре на примерах завезенных случаев лихорадки Денге проанализированы основные эпидемиологические и клинические аспекты болезни. Даны алгоритмы обследования больных с лихорадкой неясной этиологии, прибывших из тропических стран. На основании обширных данных литературы и международных рекомендаций представлены алгоритмы тактики лечения амбулаторных и стационарных больных лихорадкой Денге. Проанализированы перспективные исследования вакцинопрофилактики лихорадки Денге.

Dengue feverDengue hemorrhagic feverDengue fever with precursorssevere Dengue feverexamination of a patient with Dengue fevertreatment of Dengue feverprevention of Dengue feverdengue fevervirus diseasesdengue hemorrhagic feverлихорадка Денгегеморрагическая лихорадка ДенгеДенге с предвестникамитяжелая Денгеобследование больного Денгелечение Денгепрофилактика ДенгеИнформационный бюллетень ВОЗ №117, декабрь 2012 г. Доступно на http://www.who.int/ru/Guzman M.G., Halstead S.B., Artsob H. et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 20: S7-S16.Готовность к чрезвычайным ситуациям и реагирование на них. Лихорадка денге на Мадейре. ВОЗ 17.10.2012.Протокол совещания специалистов, осуществляющих эпидемиологический надзор за инфекционными и паразитарными болезнями, 16 мая 2013 г. Москва. Доступно на http://rospotrebnadzor.ru/.Clyde K., Kyle J.L., Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006; 20: 11418-11431.Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 20: 480-496.Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization 1997; 84.Sierra B., Kouri G., Guzman M.G. Race: a risk factor for dengue hemorrhagic fever. Arch Virology 2007; 152 (3): 533-542.Guzman A., Isturiz R.E. Update on the global spread of dengue. Int J Antimicrob Agents 2010; 20 (Suppl 1): S40-S42.Kroeger A. Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomized trials. Br Med J 2006; 332: 1247-1252.Global strategic framework for integrated vector management. Geneva, World Health Organization, 2004 (Document WHO/CDS/CPE/2004.10, available at: http://whqlibdoc.who.int/hq/2004/WHO_CDS_CPE_PVC_2004_10.pdf; accessed October 2008.Lei H.Y., Yeh T.M., Liu H.S. et al. Immunopathogenesis of dengue virus infection. J Biomed Sci 2001; 20: 377-388.Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 20: 429-436.Whitehorn J., Simmons C.P. The pathogenesis of dengue. Vaccine. 2011; 20: 7221-7228.Yacoub S., Mongkolsapaya J., Screaton G. The pathogenesis of dengue. Curr Opin Infect Dis 2013; 20: 284-289.Pandey B.D., Morita K., Hasebe F. et al. Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. Southeast Asian J Trop Med Public Health 2000; 20: 266-272.Vaughn D.W., Green S., Kalayanarooj S. et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 20: 2-9.Cologna R., Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003; 20: 3929-3938.Leitmeyer K.C., Vaughn D.W., Watts D.M. et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 20: 4738-4747.de Borba L., Strottmann D.M., de Noronha L. et al. Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1. PLoS Negl Trop Dis 2012; 20: e1624.Perng G.C., Lei H.Y., Lin Y.S., Chokephaibulkit K. Dengue vaccines: challenge and confrontation. World J Vaccin 2011; 20: 109-130.Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 20: 421-467.Ubol S., Phuklia W., Kalayanarooj S., Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis 2010; 20: 923-935.Ubol S., Halstead S.B. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol 2010; 20: 1829-1835.Halstead S.B., Mahalingam S., Marovich M.A. et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis 2010; 20: 712-722.Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 20: 532-543.Espada-Murao L.A., Morita K. Dengue and soluble mediators of the innate immune system. Trop Med Health 2011; 20: 53-62.Wan S.W., Lin C.F., Yeh T.M. et al. Autoimmunity in dengue pathogenesis. J Formos Med Assoc 2013; 20: 3-11.Halstead S.B., Heinz F.X. Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine 2005; 23 (7): 849-856.Avirutnan P., Malasit P., Seliger B. et al. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998; 161: 6338-6346.Cardier J.E. Proinflammatory factors present in sera from patients with acute dengue infection induce activation and apoptosis of human microvascular endothelial cells: possible role of TNF-alpha in endothelial cell damage in dengue. Cytokine 2005; 30 (6): 359-365.Lin Y.S., Yeh T.M., Lin C.F. et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood) 2011; 20: 515-5234.Chuang Y.C., Lin Y.S., Liu C.C. et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc 2013; 20: 12-17.Геморрагическая лихорадка денге: диагностика и лечение. ВОЗ 1988; 74.Rigau-Perez J.G., Clark G.G., Gubler D.J. et al. Dengue and dengue haemorrhagic fever. Lancet 1998; 352: 971-977.Balmaseda A., Hammond S.N., Pérez M.A. et al. Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Tropical Med Hygi 2005; 73: 1059-1062.Bandyopadhyay S., Lum L.C., Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop Med Int Health 2006; 11 (8):1238-1255.Srikiatkhachorn A., Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2009; 20: 67-82.Martina B.E., Koraka P., Osterhaus A.D. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009; 20: 564-581.Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011; 20: 587-619.Jhamb R., Kumar A., Ranga G.S., Rathi N. Unusual manifestations in dengue outbreak 2009, Delhi, India. J Commun Dis 2010; 42 (4): 255-261.Kalayanarooj S. Dengue classification: current WHO vs. the newly suggested classification for better clinical application? J Med Assoc Thai 2011; 94 (Suppl 3): S74-84.Barniol J., Gaczkowski R., Barbato E.V. et al. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis 2011; 20: 106.Международные медико-санитарные правила. ВОЗ 15.06.2007.СП 3.4.2318-08 "Санитарная охрана территории Российской Федерации".Руководство по сбору клинических образцов во время полевых расследований вспышек. WHO/CDS/CSR/EDC/2000.4МУ 3.4.3008-12 "Порядок эпидемиологической и лабораторной диагностики особо опасных, "новых" и "возвращающихся" инфекционных болезней" М 2012; 57.Cao X.T., Ngo T.N., Wills B. et al. Evaluation of the World Health Organization standard tourniquet test in the diagnosis of dengue infection in Vietnam. Tropical Med Intern Health 2002; 7: 125-132.Global strategy for dengue prevention and control 2012-2020. World Health Organization 2012; 43.Dengue diagnostics: proceedings of a joint TDR/WHO and PDVI workshop: 4-6 October 2004, Geneva, Switzerland. Pediatric Dengue Vaccine Initiative; UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. TDR/IRM/DIAG/DEN/05.1.Shu P.Y. Comparison of a capture immunoglobulin M (IgM) and IgG ELISA and non-structural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 2003; 10: 622-630.Falconar A.K., de Plata E., Romero-Vivas C.M. Altered enzyme-linked immunosorbent assay immunoglobulin M (IgM)/IgG optical density ratios can correctly classify all primary or secondary dengue virus infections 1 day after the onset of symptoms, when all of the viruses can be isolated. Clin Vaccine Immunol 2006; 13: 1044-1051.Martinez E. Preventing deaths from dengue: a space and challenge for primary health care. Pan Am J Public Health 2006; 20: 60-74.Dellinger R.P., Levy M.M., Carlet J.M. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Med 2008; 36: 296-327.Suaya J., Shepard D.S., Siqueira J.B. et al. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Tropical Med Hyg 2009; 80: 846-855.Suaya J., Shepard D.S., Beatty M.E. Dengue: burden of disease and costs of illness [working paper 3.2]. In: Report of the Scientific Working Group meeting on Dengue, Geneva, 1-5 October 2006. Geneva, World Health Organization, Special Programmer for Research and Training in Tropical Diseases 2007: 35-49.Parks W., Lloyd L.S. Planning social mobilization and communication for dengue fever prevention and control: a step-by-step guide. Geneva: World Health Organization, 2004 (available at: http://www.who.int/tdr/publications/publications/pdf/planning_dengue.pdf; accessed October 2008)].Schul W., Liu W., Xu H.Y. et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007; 195: 665-674.Patkar C.G., Kuhn R.J. Development of novel antivirals against flaviviruses. Novartis Foundation Symposium 2006; 277: 41-52.Keller T.H., Chen Y.L., Knox J.E. et al. Finding new medicines for flaviviral targets. Novartis Foundation Symposium 2006; 277: 102-114.Yauch L.E., Zellweger R.M., Kotturi M.F. et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 20: 4865-4873.Gil L., Lopez C., Lazo L. et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol 2009; 20: 1175-1183.Gil L., Lopez C., Blanco A. et al. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 2009; 20: 23-30.Zompi S., Santich B.H., Beatty P.R., Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 2012; 20: 404-416.Zompi S., Montoya M., Pohl М.О. et al. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 2012; 20: e1568.Innis B.L., Eckels K.H., Kraiselburd E. et al. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis 1998; 158: 876-880.Hombach J., Cardosa M.J., Sabchareon A. et al. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007; 25: 4130-4139.Wan S.W., Lin C.F., Wang S. et al. Current progress in dengue vaccines. J Biomed Sci 2013; 20: 37.Guy B., Barrere B., Malinowski C. et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-7241.Lang J. et al. Toward a tetravalent dengue vaccine in Brazil, Tropical Medicine meeting, Iguacu Falls, March 2010.Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Cur Opin Immunol 2011; 23: 391-398.Ng C.Y., Gu F., Phong W.Y. et al. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res 2007; 76 (3): 222-231.Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011; 29: 7276-7284.Chanthavanich P.C. Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Tropical Med Hyg 2006; 75: 26-28.Dengue guidelines for diagnosis, treatment, prevention and control: new edition World Health Organization. WHO/HTM/NTD/DEN/2009.1.